Last updated: June 27, 2026
CABTREO suppliers and contract manufacturers: who makes Cabotegravir long-acting formulations for the US market?
Who supplies the drug substance and finished product for CABTREO (cabotegravir) long-acting injections?
CABTREO is a branded long-acting injectable (cabotegravir) used in HIV therapy. For supplier identification, the controlling dataset is the US FDA “Orange Book” (NDA/BLA holder and listed patents) plus FDA CMC manufacturing information in regulatory reviews. Without those specific listings and the underlying CMC/manufacturing references, supplier-level attribution cannot be stated accurately.
What companies are listed on the Orange Book for CABTREO, and who manufactures the dosage form?
Featured-snippet answer: Orange Book records for a specific NDA must be used to identify the NDA holder and any listed manufacturing site details. Supplier names tied to CABTREO require direct extraction from the Orange Book and corresponding FDA labeling/manufacturing sections tied to the commercial product.
Which contract manufacturing organizations (CMOs) produce CABTREO injections and fill-finish?
CMO and fill-finish attribution for CABTREO requires the exact CABTREO NDA number and the manufacturing site designations (drug substance vs drug product) stated in FDA labeling or CMC. Without those exact FDA references, naming specific CMOs risks misattribution.
How strong is the patent estate for CABTREO, and does it affect supply chain availability?
Patent protection does not reliably identify suppliers. Supply continuity is driven by manufacturing authorizations and approved CMC changes, not by patent holder identity alone. Accurate mapping of patent-protected manufacturing steps requires a patent-by-patent construction from the Orange Book plus any relevant litigation or consent decrees.
What patent litigation or settlements could constrain CABTREO generic or biosimilar supply?
For CABTREO, any generic entry risk is typically assessed through ANDA Paragraph IV certifications and any related litigation tied to the Orange Book patents. Supplier constraints from litigation are only determinable with: (1) the Orange Book patent list, (2) the Paragraph IV history, and (3) docketed settlement terms. Those particulars are not available in the prompt.
What formulations and strengths of CABTREO exist, and do different strengths use different suppliers?
Supplier networks often split by strength, vial size, and fill-finish batch architecture. Determining whether CABTREO strengths (and related presentations) are produced by different sites requires the specific FDA label package insert manufacturing/distribution sections, which are not provided.
When does CABTREO lose exclusivity, and how does timing affect supplier strategy?
Exclusivity calendars must be tied to the CABTREO NDA’s regulatory exclusivity periods and patent expiration schedule from FDA records. Without the NDA number, first approval date, and the exclusivity/patent schedule, loss-of-exclusivity timing cannot be computed.
How many patents cover CABTREO manufacturing, method-of-use, and formulations?
Counting patents for CABTREO requires the complete Orange Book patent list (with expiration dates and patent categories). Patent count is not computable without the exact listing.
Which international suppliers could serve non-US markets for CABTREO?
International manufacturing and distribution depend on country approvals, local regulatory filings, and national listings. Cross-market supplier mapping requires country-specific regulatory datasets, not provided here.
Key Takeaways
- CABTREO supplier identification requires the exact FDA Orange Book/NDA-linked manufacturing and labeling records for cabotegravir long-acting injection.
- Without the CABTREO NDA number and the FDA manufacturing-site designations for drug substance and drug product, specific supplier and CMO attribution cannot be produced.
FAQs
- How do I identify the NDA holder and patent holder for CABTREO from FDA data?
- Which CABTREO manufacturing sites are typically listed as drug substance vs drug product in FDA submissions?
- Do CABTREO strength-specific presentations use separate fill-finish suppliers?
- What data sources best capture CABTREO CMO and contract packaging for litigation discovery?
- How does CABTREO exclusivity timing map to expected generic supply chain readiness?
References
No sources were cited because the prompt does not include CABTREO’s NDA number, Orange Book listings, or FDA label/manufacturing records.
